Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 14/20 | 0.48 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL589752 | 1.00 | ADORA2A (0.48) | ADORA2ACCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL5223993 | 0.88 | CCNE2 (0.45) | ADORA2ACCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL4668074 | 0.88 | CCNE2 (0.45) | ADORA2ACCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL4668071 | 0.88 | CCNE2 (0.45) | ADORA2ACCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL5223984 | 0.88 | CCNE2 (0.45) | ADORA2ACCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL4669301 | 0.88 | CCNE2 (0.45) | ADORA2ACCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL591167 | 0.88 | CCNE2 (0.45) | ADORA2ACCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL3161155 | 0.88 | CCNE2 (0.45) | ADORA2ACCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL591168 | 0.88 | CCNE2 (0.45) | ADORA2ACCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL589460 | 0.86 | ADORA2A (0.63) | ADORA2ACCNE2CCNA2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114877-B2 | Antiinflammatory agnets; chronic obstructive pulmonary diseases | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| EP-2012759-B1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2010-03-10 | — | — | EP | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| EP-1841768-B1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093633-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885CCNE2 2913/4885CCNA2 2632/4885 |
| US-20080207648-A1 | Organic Compounds | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885CCNE2 1717/4885CCNA2 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.